Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Minerva Neurosciences, Inc.

Minerva Neurosciences focuses on clinical development in central nervous system disorders, designing innovative trials aimed at patient benefit.

COM:MINERVANEUROSCIENCES

Minerva Neurosciences

Last Close

2.12

21/11 21:00

Market Cap

15.46M

Beta: -

Volume Today

17.32K

Avg: -